For many patients, standard chemotherapy regimens provide the best possibility of long-term survival. They have strange names like CHOP, which stands for Cytoxan® (cyclophosphamide), doxorubicin hydrochloride (Adriamycin®), Oncovin® (vincristine) and Prednisone, the four cancer drugs that are used.
For most patients, these chemotherapy regimens provide fairly predictable results and are the first choice in treating the cancer. If the regimen fails, the medical oncologist can opt for a clinical trial – a research protocol that may use new chemotherapeutic drugs or use new combinations of drugs. Sometimes standard treatments offer poor chances of long-term survival and a clinical trial holds out new hope to patients.
The Medical Oncology Department of The Cancer Center of Cape Fear Valley Health System has been offering clinical trials for many years. These clinical research studies determine the possible benefits of new and innovative therapies.
The only way to prove the potential benefits of a new treatment is to perform a clinical trial. By conducting a clinical trial, we are able to determine the risks and benefits of a new drug regimen and then compare those risks and advantages to standard therapy used in the past.
There are four research phases of a clinical trial:
Most clinical trials involve new treatments for disease. One trial that is actively enrolling participants is a study to determine whether a drug will prevent cancer in a high-risk population. An affiliate of the Lineburger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, The Cancer Center has been actively recruiting participants for one of the largest breast cancer studies ever, the Study of Tamoxifen and Raloxifene, or (STAR) trial.
The STAR trial is enrolling postmenopausal women who are at risk of breast cancer to determine whether the osteoporosis-prevention drug raloxifene (Evista®) is as effective in reducing the chance of developing breast cancer as tamoxifen (Nolvadex®) has proven to be.
The Cancer Center’s STAR trial is a Phase III study comparing the risks and benefits of raloxifene to the risks and benefits of tamoxifen. Tamoxifen has been shown to reduce the chance of developing breast cancer by approximately 50 percent in the Breast Cancer Prevention Trial published in the Journal of the National Cancer Institute on Sept. 16, 1998. In the Breast Cancer Prevention Trial, half of the women took tamoxifen and half took a placebo (an inactive pill).
Breast cancer patients whose tumors are estrogen-positive are routinely offered tamoxifen as a part of their therapy. Most breast cancer patients continue to take the drug for five years.
Another clinical trial being conducted at The Cancer Center is the Phase III Randomized Study of Adjuvant Immunotherapy with Monoclonal Antibody 17-1A. This trial investigates the benefits of the Monoclonal Antibody 17-1A in the treatment of colon cancer after surgery. Researchers want to know if Monoclonal Antibody 17-1A is more beneficial than chemotherapy, which is the standard treatment for some patients following a resection for stage II colon cancer. It appears that the Monoclonal Antibody attacks only the tumor cells, unlike chemotherapy, which attacks all cells. According to Dr. Bakri, this is good news if the preliminary findings hold true.
Clinical trials provide advances in medicine and science. New cancer treatments must be proven to be safe and effective. Through these scientific studies, researchers are able to conclude which methods of treatment are most successful.
There are many advantages to enrolling in a clinical trial at The Cancer Center. Not only does the participant benefit from a study that may prove to be a superior treatment, but others also benefit from the increased knowledge that the study discloses.
Pam Clark, RN, is the Research Coordinator in the Medical Oncology Department at The Cancer Center. Ms. Clark determines if the patient meets all eligibility requirements necessary to participate in a clinical trial. She also provides information on current studies and answers questions regarding the safety and side effects of the treatment.
An Institutional Review Board (IRB) oversees the action plan or protocol related to each clinical trial conducted at The Cancer Center. The IRB is comprised of physicians, medical specialists, nurses, social workers, medical ethicists and patient advocates who have no special interest in any specific trial. IRB members are responsible for reviewing protocols to ensure that patients are not exposed to unethical risks. These boards also ensure that trials are conducted with the full consent of the patient.
Participating in a study is completely voluntary. Clinical trials do require that a participant be able to receive a treatment and submit to monitoring and follow-ups. However, patients who join a study are free to withdraw at any time.
In most cases, patients and the trial sponsors are financially responsible for clinical trial costs. Drugs offered in the study may be supplied by the pharmaceutical company through the National Cancer Institute; however, patients participating in the study may be responsible for routine costs, such as doctor visits, lab tests, scans, x-rays and hospital fees.
Clinical research studies add to our knowledge and progress against cancer. Patients who take part may be among the first to benefit from innovative therapy and as a result, provide useful information, which will aid many others.
Those interested in learning whether they are candidates for one of numerous clinical trials being conducted at The Cancer Center Oncology Research Department should contact the Oncology Research Coordinator at (910) 615-4561